Clinical Trials

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT01386385 2026-03-18

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

53 enrolled 21 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04001829 2026-03-13

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

249 enrolled 14 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Breast Neoplasms

NCT04205812 2026-03-10

POD1UM-304

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT05775289 2026-02-11

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

182 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung

NCT01081951 2026-02-05

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

162 enrolled 15 charts

Ovarian Neoplasms

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

23 enrolled 18 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03742102 2026-02-02

BEGONIA

243 enrolled 13 charts

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04391049 2026-01-30

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

16 enrolled 15 charts

Carcinoma, Squamous Cell, Neoplasms, Squamous Cell

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT04269200 2025-12-23

DUO-E

805 enrolled 18 charts 1 FDA

Phase 1 Active not recruiting

Endometrial Neoplasms

NCT05276973 2025-12-19

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

25 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02259621 2025-12-03

NA_00092076

39 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01142388 2025-11-25

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

94 enrolled 8 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

92 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04425018 2025-11-18

MARGOT

174 enrolled 19 charts

Breast Neoplasms

NCT04175912 2025-11-17

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

40 enrolled 11 charts

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT06212752 2025-11-12

MK-3475A-D77

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03740165 2025-10-22

KEYLYNK-001

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04623775 2025-10-20

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

468 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT02883062 2025-10-16

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

461 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03965689 2025-09-22

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

27 enrolled 13 charts

Lung Neoplasms

NCT05722015 2025-09-11

MK-3475A-D77

377 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02957968 2025-08-28

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00070564 2025-07-31

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

3,294 enrolled 22 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT04331067 2025-04-23

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

15 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT03568422 2025-03-25

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

37 enrolled 14 charts

Breast Neoplasms

NCT02734290 2025-03-10

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

29 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04215146 2025-01-16

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

48 enrolled 13 charts

Breast Neoplasms

NCT04956692 2024-12-03

MK-3475-A86

531 enrolled 18 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

62 enrolled 7 charts